Visiox Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Visiox Pharma's estimated annual revenue is currently $310k per year.
- Visiox Pharma's estimated revenue per employee is $77,500
Employee Data
- Visiox Pharma has 4 Employees.
- Visiox Pharma grew their employee count by 100% last year.
Visiox Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO & Director | Reveal Email/Phone |
Visiox Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Visiox Pharma?
Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals. Our first asset, PDP-716, is a once-daily brimonidine for ocular hypertension and open angle glaucoma. Our second asset, SDN-037, is a twice daily topical difluprednate for post-surgical inflammation and pain. Each product utilizes a unique, proprietary, extended release technology that is patent protected through at least 2036.
keywords:N/AN/A
Total Funding
4
Number of Employees
$310k
Revenue (est)
100%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 5 | 0% | N/A |
#2 | $0.4M | 5 | -29% | N/A |
#3 | $0.5M | 7 | 0% | N/A |
#4 | $0.5M | 7 | 0% | N/A |
#5 | N/A | 8 | -76% | N/A |